Skip to main content

Table 3 Adverse events during chemoradiotherapy (n = 95)

From: Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study

 

G1 + G2 (%)

G3 + G4 (%)

 

NATRACE-CRT

NA-CRT

P-value

NATRACE-CRT

NA-CRT

P-value

Leukopenia

7 (14.00)

3 (6.67)

0.324

3 (6.00)

2 (4.44)

0.735

Neutropenia

3 (6.00)

1 (2.22)

0.619

1 (2.00)

1 (2.22)

0.941

Anemia

8 (16.00)

6 (13.33)

0.778

   

Thrombocytopenia

3 (6.00)

1 (2.22)

0.619

1 (2.00)

1 (2.22)

0.941

Febrile neutropenia

0

1 (2.22)

NA

 

1 (2.22)

NA

AST

0

1 (2.22)

NA

   

ALT

0

1 (2.22)

NA

   

Total bilirubin

1 (2.00)

1 (2.22)

0.941

   

Nausea

15 (30.00)

11 (24.44)

0.647

   

Vomiting

4 (8.00)

3 (6.67)

0.804

   

Fatigue

12 (24.00)

11 (24.44)

0.960

   

Diarrhea

12 (24.00)

9 (20.00)

0.805

   

Appetite loss

16 (32.00)

18 (40.00)

0.521

   

Hand–foot syndrome

1 (2.00)

0

NA

   

Radiation proctitis

15 (30.00)

12 (26.67)

0.719

1 (2.00)

2 (4.44)

0.496

  1. Abbreviations: AST aspartate aminotransferase, ALT alanine aminotransferase. National Cancer Institute Common Toxicity Criteria, version 4.0
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us